Who are Bristol Myers Squibb's decision-makers?
Bristol Myers Squibb is led by Christopher Boerner. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Christopher Boerner
- CFO/key exec
- David Elkins
- Founded
- 1887
- Employees
- 34,000+
- HQ
- Princeton, NJ
- Status
- NYSE: BMY
- Christopher BoernerBoard Chair and Chief Executive OfficerCEO since 2023; board chair in 2025Leads the Growth Portfolio transition and pipeline execution.
- David ElkinsExecutive Vice President and Chief Financial OfficerCFO since 2024Owns finance, capital allocation, and productivity planning.
- Samit HirawatChief Medical Officer, Global Drug DevelopmentSenior R&D leaderGuides clinical development and portfolio prioritization.
- Adam LenkowskyChief Commercialization OfficerSenior commercial leaderLeads global commercialization across growth and legacy brands.
Who leads Bristol Myers Squibb?
Bristol Myers Squibb's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Bristol Myers Squibb?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Bristol Myers Squibb organized as it scales?
Bristol Myers Squibb operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Bristol Myers Squibb leadershipBristol Myers Squibb annual reports
Bristol Myers Squibb — frequently asked questions
